ESR1 and breast cancer: Furthermore, a subset of ER+ breast cancers with defects in MutL mismatch repair [19] and DNA damage repair [20] exhibit resistance to all classes of endocrine therapy, yet preclinical data indicate that such tumors still respond to CDK4/6i.